CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction?

[1]  T. Takano,et al.  Complement C5b-9-mediated arachidonic acid metabolism in glomerular epithelial cells : role of cyclooxygenase-1 and -2. , 2000, The American journal of pathology.

[2]  G. Baxter,et al.  Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury , 2000, British journal of pharmacology.

[3]  S. Meri,et al.  Complement activation after oxidative stress: role of the lectin complement pathway. , 2000, The American journal of pathology.

[4]  C. Alpers,et al.  C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis. , 2000, American journal of physiology. Renal physiology.

[5]  C. Hack,et al.  C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. , 2000, Pharmacological reviews.

[6]  M. Pepys,et al.  C-Reactive Protein and Complement Are Important Mediators of Tissue Damage in Acute Myocardial Infarction , 1999, The Journal of experimental medicine.

[7]  C. Boissonnet,et al.  Independent prognostic value of elevated C-reactive protein in unstable angina. , 1999, Circulation.

[8]  K. Kugiyama,et al.  Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. , 1999, Circulation.

[9]  C. Visser,et al.  C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? , 1999, Circulation.

[10]  M. Daha,et al.  The terminal sequence of complement plays an essential role in antibody-mediated renal cell apoptosis. , 1999, Journal of the American Society of Nephrology : JASN.

[11]  John D Lambris,et al.  The evolution, structure, biology and pathophysiology of complement. , 1999, Immunology today.

[12]  C. Visser,et al.  Upregulation of ICAM-1 on cardiomyocytes in jeopardized human myocardium during infarction. , 1999, Cardiovascular research.

[13]  P. Mcgeer,et al.  Human heart generates complement proteins that are upregulated and activated after myocardial infarction. , 1998, Circulation research.

[14]  P. Mcgeer,et al.  Complement gene expression by rabbit heart: upregulation by ischemia and reperfusion. , 1998, Circulation research.

[15]  L. Matis,et al.  Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. , 1998, Circulation.

[16]  Ridker Pm,et al.  C-reactive protein and risks of future myocardial infarction and thrombotic stroke. , 1998 .

[17]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[18]  C. Schalkwijk,et al.  A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. , 1997, Immunology today.

[19]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.

[20]  G. Horstick,et al.  Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. , 1997, Circulation.

[21]  C. Visser,et al.  C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. , 1997, Circulation.

[22]  J. Schofer,et al.  Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits. , 1996, Cardiovascular research.

[23]  P. Ward,et al.  Requirement and role of C5a in acute lung inflammatory injury in rats. , 1996, The Journal of clinical investigation.

[24]  I. T. Ten Berge,et al.  CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. , 1996, Journal of immunology.

[25]  P. Ward,et al.  Up-regulation of lung vascular ICAM-1 in rats is complement dependent. , 1995, Journal of immunology.

[26]  A. Manning,et al.  Protection of ischemic/reperfused canine myocardium by CL18/6, a monoclonal antibody to adhesion molecule ICAM-1. , 1995, Cardiovascular Research.

[27]  L. Sarda,et al.  Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells , 1995, Cell.

[28]  M. Casl,et al.  Serum Amyloid a Protein in Patients with Acute Myocardial Infarction , 1995, Annals of clinical biochemistry.

[29]  A. M. Lefer,et al.  Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. , 1995, Circulation.

[30]  S. Rendig,et al.  Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. , 1995, The American journal of physiology.

[31]  M. Cicardi,et al.  Activation of Complement and Kinin Systems After Thrombolytic Therapy in Patients With Acute Myocardial Infarction: A Comparison Between Streptokinase and Recombinant Tissue‐Type Plasminogen Activator , 1994, Circulation.

[32]  M. Entman,et al.  Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. , 1994, Cardiovascular research.

[33]  R. Reneman,et al.  Ischemia And Reperfusion Induced Alterations In Membrane Phospholipids: An Overview a , 1994, Annals of the New York Academy of Sciences.

[34]  B. Lucchesi,et al.  The complement system in myocardial ischaemia/reperfusion injury. , 1994, Cardiovascular research.

[35]  J. Schofer,et al.  Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion. , 1994, European heart journal.

[36]  M. Weisfeldt,et al.  Soluble Complement Receptor Type 1 Inhibits the Complement Pathway and Prevents Contractile Failure in the Postischemic Heart Evidence That Complement Activation Is Required for Neutrophil‐Mediated Reperfusion Injury , 1993, Circulation.

[37]  M. Entman,et al.  Regulation of intercellular adhesion molecule-1 (ICAM-1) in ischemic and reperfused canine myocardium. , 1993, The Journal of clinical investigation.

[38]  S. Meri,et al.  Regulation of complement membrane attack complex formation in myocardial infarction. , 1993, The American journal of pathology.

[39]  R. Virmani,et al.  Myocardial infarct extension during reperfusion after coronary artery occlusion: pathologic evidence. , 1993, Journal of the American College of Cardiology.

[40]  C. Smith,et al.  CD18-dependent adherence reactions play an important role in the development of the no-reflow phenomenon. , 1993, The American journal of physiology.

[41]  W. Sluiter,et al.  Leukocyte adhesion molecules on the vascular endothelium: their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression. , 1993, Journal of cardiovascular pharmacology.

[42]  M. Entman,et al.  Neutrophil induced oxidative injury of cardiac myocytes. A compartmented system requiring CD11b/CD18-ICAM-1 adherence. , 1992, The Journal of clinical investigation.

[43]  J. Baars,et al.  Interplay of complement and cytokines in the pathogenesis of septic shock. , 1992, Immunopharmacology.

[44]  B. Lucchesi,et al.  Effects of complement activation in the isolated heart. Role of the terminal complement components. , 1992, Circulation research.

[45]  M. Entman,et al.  Neutrophil adherence to isolated adult cardiac myocytes. Induction by cardiac lymph collected during ischemia and reperfusion. , 1992, The Journal of clinical investigation.

[46]  D. Fearon.  ANTI‐INFLAMMATORY AND IMMUNOSUPPRESSIVE EFFECTS OF RECOMBINANT SOLUBLE COMPLEMENT RECEPTORS , 1991, Clinical and experimental immunology.

[47]  K. Pietilä,et al.  Acute phase reaction, infarct size and in-hospital morbidity in myocardial infarction patients treated with streptokinase or recombinant tissue type plasminogen activator. , 1991, Annals of medicine.

[48]  Steven D. Carson,et al.  Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. , 1990, Blood.

[49]  G. R. Carson,et al.  Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. , 1990, Science.

[50]  D. Mathey,et al.  Quantitative measurement of SC5b‐9 and C5b‐9(m) in infarcted areas of human myocardium , 1990, Clinical and experimental immunology.

[51]  C. Esmon,et al.  Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. , 1990, The Journal of biological chemistry.

[52]  G. R. Carson,et al.  Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. , 1990, Transactions of the Association of American Physicians.

[53]  I. Toda,et al.  The complement system in ischemic heart disease. , 1990, Circulation.

[54]  M. Hostetter,et al.  The erythrocyte as instigator of inflammation. Generation of amidated C3 by erythrocyte adenosine deaminase. , 1989, The Journal of clinical investigation.

[55]  M. Entman,et al.  Molecular Basis of Complement Activation in Ischemic Myocardium: Identification of Specific Molecules of Mitochondrial Origin That Bind Human Clq and Fix Complement , 1989, Circulation research.

[56]  L. McManus,et al.  Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. , 1988, Circulation.

[57]  D. Fearon,et al.  Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis , 1988, The Journal of experimental medicine.

[58]  P. J. Simpson,et al.  Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. , 1988, The Journal of clinical investigation.

[59]  R. Bolli,et al.  Activation of the complement system by recombinant tissue plasminogen activator. , 1987, Journal of the American College of Cardiology.

[60]  L. Becker,et al.  Myocardial consequences of reperfusion. , 1987, Progress in cardiovascular diseases.

[61]  D. Fearon,et al.  Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins , 1987, The Journal of experimental medicine.

[62]  M. Shin,et al.  Nucleated cell killing by complement: effects of C5b-9 channel size and extracellular Ca2+ on the lytic process. , 1987, Journal of immunology.

[63]  H. Silverman,et al.  Relation between use of anti-inflammatory agents and left ventricular free wall rupture during acute myocardial infarction. , 1987, The American journal of cardiology.

[64]  D. Mathey,et al.  Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. , 1986, Journal of immunology.

[65]  G. Schmid-Schönbein,et al.  Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. , 1986, The American journal of physiology.

[66]  G. Schmid-Schönbein,et al.  Accumulation of polymorphonuclear leukocytes during 3-h experimental myocardial ischemia. , 1986, The American journal of physiology.

[67]  D. Renlund,et al.  A Phosphorus‐31 Nuclear Magnetic Resonance Study of the Metabolic, Contractile, and Ionic Consequences of Induced Calcium Alterations in the Isovolumic Rat Heart , 1986, Circulation research.

[68]  K. Swedberg,et al.  Rupture of the myocardium. Occurrence and risk factors. , 1985, British heart journal.

[69]  M. Entman,et al.  Selective Accumulation of the First Component of Complement and Leukocytes in Ischemic Canine Heart Muscle: A Possible Initiator of an Extra Myocardial Mechanism of Ischemic Injury , 1985, Circulation research.

[70]  M. Polley,et al.  Cardiac dysfunction caused by purified human C3a anaphylatoxin. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[71]  M. Schork,et al.  Reduction of the Extent of Ischemic Myocardial Injury by Neutrophil Depletion in the Dog , 1983, Circulation.

[72]  L. McManus,et al.  Complement localization in ischemic baboon myocardium. , 1983, Laboratory investigation; a journal of technical methods and pathology.

[73]  G. Schmid-Schönbein,et al.  Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. , 1983, The American journal of pathology.

[74]  J. Tschopp,et al.  Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9 , 1982, Nature.

[75]  J. Volanakis.  COMPLEMENT ACTIVATION BY C‐REACTIVE PROTEIN COMPLEXES * , 1982, Annals of the New York Academy of Sciences.

[76]  W. Hoppe,et al.  Membrane attach complex of complement (MAC): three-dimensional analysis of MAC-phospholipid vesicle recombinants. , 1982, Journal of immunology.

[77]  V. Hu,et al.  The membrane attack mechanism of complement: photolabeling reveals insertion of terminal proteins into target membrane. , 1981, Journal of immunology.

[78]  J. Volanakis,et al.  Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement. , 1981, Journal of immunology.

[79]  L. McManus,et al.  Complement localization and mediation of ischemic injury in baboon myocardium. , 1980, The Journal of clinical investigation.

[80]  A. D. Smith,et al.  An improved method for the isolation from Naja naja venom of cobra factor (CoF) free of phospholipase A. , 1979, Journal of immunological methods.

[81]  M. Chiariello,et al.  Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. , 1978, The Journal of clinical investigation.

[82]  H. Müller-Eberhard,et al.  Anaphylatoxins: C3a and C5a. , 1978, Advances in immunology.

[83]  A. Allison,et al.  Further link between complement activation and blood coagulation , 1977, Nature.

[84]  R Roberts,et al.  Deleterious effects of methylprednisolone in patients with myocardial infarction. , 1976, Circulation.

[85]  M. Pepys.  Studies in vivo of cobra factor and murine C3. , 1975, Immunology.

[86]  A. M. Lefer,et al.  Protective Action of Methylprednisolone on the Myocardium during Experimental Myocardial Ischemia in the Cat , 1974, Circulation research.

[87]  J. Volanakis,et al.  Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. , 1974, Journal of immunology.

[88]  H. Müller-Eberhard,et al.  Interactions between human C5, C6, and C7 and their functional significance in complement-dependent cytolysis. , 1973, Journal of immunology.

[89]  P. Libby,et al.  Reduction of experimental myocardial infarct size by corticosteroid administration. , 1973, The Journal of clinical investigation.

[90]  Y. Kanter,et al.  Use of hydrocortisone in the treatment of acute myocardial infarction. Summary of a clinical trial in 446 patients. , 1972, Chest.

[91]  P. Ward,et al.  THE PHLOGISTIC ROLE OF C3 LEUKOTACTIC FRAGMENTS IN MYOCARDIAL INFARCTS OF RATS , 1971, The Journal of experimental medicine.

[92]  P. Ward.  A PLASMIN-SPLIT FRAGMENT OF C'3 AS A NEW CHEMOTACTIC FACTOR , 1967, The Journal of experimental medicine.

[93]  O. Ratnoff,et al.  THE CONVERSION OF C'1S TO C'1 ESTERASE BY PLASMIN AND TRYPSIN , 1967, The Journal of experimental medicine.

[94]  A. Peel,et al.  A TRIAL OF HYDROCORTISONE IN ACUTE MYOCARDIAL INFARCTION , 1963 .

[95]  M. H. Kaplan,et al.  Studies of acute-phase protein. II. Localization of Cx-reactive protein in heart in induced myocardial infarction in rabbits. , 1963, The Journal of clinical investigation.

[96]  H. C. Saltzstein,et al.  Effect of Cortisone on the Size of Experimentally Produced Myocardial Infarcts , 1953, Journal - Michigan State Medical Society.